Literature DB >> 11448121

Interleukin 1 components in cicatricial pemphigoid. Role in intravenous immunoglobulin therapy.

S Kumari1, K C Bhol, F Rehman, C S Foster, A R Ahmed.   

Abstract

Interleukin (IL-)1 is an important mediator of inflammatory responses and plays an important role in the pathogenesis of various autoimmune diseases. Cicatricial pemphigoid (CP) is a multisystem autoimmune inflammatory disease. We have studied the role of IL-1 in its pathogenesis. We have investigated the serum levels of IL-1 components (IL-1alpha, IL-1beta, and IL-1Ra), and determined the role of intravenous immunoglobulin (IVIg) therapy in patients with CP. Serum levels of IL-1alpha and beta were significantly higher in untreated patients with active disease compared to levels in patients in prolonged clinical remission and normal human controls (P<0.0001). The serum levels of IL-1Ra were higher in patients in prolonged clinical remission compared to patients with active disease (P=0.002). Hence elevated levels of IL-1alpha and beta and low levels of IL-1Ra correlate with disease activity. The levels of IL-1alpha and beta were statistically significantly higher in sera of CP patients with active disease pre-IVIg therapy compared to post-IVIg therapy (P<0.0001). Statistically significantly higher levels of IL-1Ra were present in post-IVIg treatment serum samples when compared to levels in pre-IVIg treatment (P<0.0001). In the in vitro experiments, the levels of IL-1alpha and beta produced by the peripheral blood mononuclear cells (PBMC) isolated from patients before IVIg therapy were significantly higher when compared to the PBMC isolated from post-IVIg patients (P<0.0001). Significantly higher levels of IL-1Ra were observed in the supernatants of PBMC collected from pre-IVIg patients and cultured with exogenously added IVIg, when compared to the levels of PBMC to which IVIg was not added (P<0.0001). IL-1 may be an important cytokine involved in the pathogenesis of CP. The regulation of IL-1 could be one of the mechanisms, amongst others, by which IVIg may exert its beneficial effect in the treatment of CP. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11448121     DOI: 10.1006/cyto.2001.0877

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  4 in total

Review 1.  Intravenous immunoglobulin in eye involvement.

Authors:  Zera Tellier
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 2.  Autoimmunity at the ocular surface: pathogenesis and regulation.

Authors:  M E Stern; C S Schaumburg; R Dana; M Calonge; J Y Niederkorn; S C Pflugfelder
Journal:  Mucosal Immunol       Date:  2010-05-19       Impact factor: 7.313

Review 3.  High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases.

Authors:  Norito Ishii; Takashi Hashimoto; Detlef Zillikens; Ralf J Ludwig
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

Review 4.  Proteases in Pemphigoid Diseases.

Authors:  Sho Hiroyasu; Christopher T Turner; Katlyn C Richardson; David J Granville
Journal:  Front Immunol       Date:  2019-06-26       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.